| Contraception |
1 |
1 |
| Intrauterine Device |
0 |
0.84 |
| Pregnancy |
0 |
0.44 |
| A-Scan Biometry |
0 |
0.36 |
| Scan |
0 |
0.36 |
| Care and Maintenance of Vision |
0 |
0.27 |
| Cataract |
0 |
0.27 |
| Adverse Effects |
0 |
0.24 |
| Estrogen |
0 |
0.24 |
| Liver |
0 |
0.24 |
| Patient Safety |
0 |
0.18 |
| Thromboembolism |
0 |
0.15 |
| Biomarker |
0 |
0.12 |
| Breast |
0 |
0.12 |
| Emergency Contraception |
0 |
0.12 |
| Fertility |
0 |
0.12 |
| Food and Drug Administration (FDA) |
0 |
0.12 |
| Health Care Quality, Access, and Evaluation |
0 |
0.12 |
| Hemorrhage |
0 |
0.12 |
| Hormonal Contraception |
0 |
0.12 |
| Hormonal Therapy |
0 |
0.12 |
| Progestin |
0 |
0.12 |
| Vagina |
0 |
0.12 |
| Venous Thromboembolism (VTE) |
0 |
0.12 |
| Social Determinants of Health |
0 |
0.09 |